NewsBenzingaJohnson & Johnson Announces Three-Year Data From Its Phase 3 GALAXI 2, 3 Trials Of TREMFYA Demonstrate Efficacy, Consistent Profile To Treat Crohn's Disease Johnson & Johnson Announces Three-Year Data From Its Phase 3 GALAXI 2, 3 Trials Of TREMFYA Demonstrate Efficacy, Consistent Profile To Treat Crohn's Disease Benzinga 2026.10.12 20:12 (GMT+0) Open on Benzinga Other news JPMorgan Extends JPM Coin to Ethereum for Institutional Clients Nasdaq Tumbles Over 2%, Records Weekly Loss: Investor Sentiment Weakens, Fear & Greed Index Moves to ‘Extreme Fear’ Zone Fifth Third Bancorp, Cleveland-Cliffs and 3 Stocks to Watch Heading Into Monday WGMI’s Pivot: From Bitcoin Miner To AI Power Play (Upgrade) (NASDAQ:WGMI) Weekly Market Pulse: Reality Bites (null:SPX) Exelon: Shelter From The Storm And Nice Yield As Utilities Catch A Bid (NASDAQ:EXC)
Nasdaq Tumbles Over 2%, Records Weekly Loss: Investor Sentiment Weakens, Fear & Greed Index Moves to ‘Extreme Fear’ Zone
